SLC5A2 and chronic kidney disease: Moreover, sodium/glucose cotransporter 2 (SGLT2) inhibitors, a novel highly efficacious drug targeting glycemic control, have multifaceted benefits in nephrology, cardiology, endocrinology, and primary care, and are expected to further optimize the benefits of glycemic control in patients with diabetes and CKD [35].